

Supplementary information

1 Supplementary Figures



Supplementary Figure 1: A tumor's priming rate affects the location of a tipping point.

(A) In the absence of T cell priming, survival is only determined by the tumor growth rate. Logically, a tipping point cannot be present. Priming rate $\alpha = 0$. (B-D) Higher T cell priming rates lead to increased availability of cytotoxic T cells. As a result, despite a similar killing rate, the augmented T cell pool can clear tumors with a higher priming rate more easily. These findings are visible as a shifting tipping point in the phase diagrams. As stated in the Methods, a priming rate of 0.0025 is mechanistically plausible and, therefore, selected as the default priming rate (indicated with a *). Parameter values for low and high priming rates are $\alpha = 0.00125$ and $\alpha = 0.025$, respectively.



Supplementary Figure 2: Tumor-immune dynamics determine the clinical outcome of patients in close proximity to a tipping point.

2 Supplementary Tables

Supplementary Table 1: Simulation parameters of Figure 1

rapprenientary radio in communication parameters of rigario i				
Panel	Simulation parameters			
Overall	ρ = 1			
В	ξ = 0.005			
С	ξ = 0.00025			
D	ξ = 0.0005			

Supplementary Table 2: Simulation parameters of Figure 2

Panel	Simulation parameters				
Α	Main: ρ = range from 0 to 7, ξ = 0.005				
	Inset 1: $\rho = 2$, $\xi = 0.005$				
	Inset 2: $\rho = 5.5$, $\xi = 0.005$				
В	Main: $\rho = 6$, $\xi = \text{range from 0 to 0.005}$				
	Inset 1: $\rho = 6$, $\xi = 0.005$				
	Inset 2: $\rho = 6$, $\xi = 0.035$				
С	ρ = range from 0 to 7				
	ξ = range from 0 to 0.05				

Supplementary Table 3: Simulation parameters of Figure 3

Panel	Simulation parameters
B/C	Main: $\rho = 2$, $\xi = 0.001$
	Variation in treatment effect and treatment duration are indicated on the x-axes of the figures.
D	Baseline values for the T cell killing rate were fixed at ξ = 0.0025.
	Baseline values for the tumor growth rate (ρ) were sampled from a normal
	distribution: $\rho \sim N(2.5, 1)$. We included only patients (n = 20) with clinically evident
	tumors.
E	Baseline values for the tumor growth rate were fixed at ρ = 2.5.
	Baseline values for the T cell killing rate (ξ) were sampled from a uniform
	distribution: $\xi \sim U$ (0, 0.005). We included only patients (n = 20) with clinically
	evident tumors.

Supplementary Table 4: Simulation parameter of Figure 4

Panel	Simulation parameters			
Overall	Treatment effect = ξ * 12.5			
Α	ρ = 2, ξ = 0.001, stochasticity tumor growth rate = 0.3			
В	ρ = 2, ξ = 0.001, stochasticity T cell killing rate = 0.3			
С	Baseline values were sampled from two normal distributions: • $\rho \sim N(2.5, 1)$ • $\xi \sim N(0.0025, 0.001)$ We select patients (n = 12) with clinically evident tumors and rejected all patients in which tumors did not exceed the diagnosis threshold. Stochasticity tumor growth rate = 0.3, stochasticity T cell killing rate = 0.3			
D	ρ = range from 0 to 7, ξ = 0.005, stochasticity tumor growth rate = 0.3			
E	ρ = 6, ξ = range from 0 to 0.05, stochasticity T cell killing rate = 0.3			

Supplementary Table 5: Simulation parameters of Figure 5

Panel	Simulation parameters			
Overall	Baseline values sampled from two uniform distributions:			
	• ρ~ U (4, 5)			

	• ξ ~ <i>U</i> (0.015, 0.025)				
	Simulations where the tumor did not become clinically apparent (i.e., did not reach a size of $65 * 10^8$ tumor cells) were not included in the analysis.				
Α	Treatment effect = ξ * 4				
В	Treatment effect = ξ * 4				
	Stochasticity in tumor growth rate = 0.05				
	Stochasticity in T cell killing rate = 0.05				

Supplementary Table 6: Baseline characteristics of retrospective validation cohort.

	Overall (N=58)	
Gender		
Female	21 (36.2%)	
Male	37 (63.8%)	
Age (years)		
Median [Min, Max]	51.0 [19.0, 76.0]	
Breslow thickness (mm)		
Median [Min, Max]	2.65 [0.7, 13.0]	
M stage at inclusion		
M1a	13 (22.4%)*	
M1b	14 (24.1%)	
M1c	31 (53.4%)	
LDH (U/L)		
Median [Min, Max]	388 [228, 1830]	
Time to M stage (months)		
Median [Min, Max]	29.3 [0, 137]	
Overall Survival (months)		
Median [Min, Max]	8.92 [1.15, 130]	

^{*} Includes one irresectable stage III melanoma patient.

Supplementary Table 7: Cox proportional hazard models on validation cohort.

Model	N	HR*	95% CI	Wald statistic	Likelihood ratio test
LDH	58	6.92	(2.93 - 16.31)	$p = 1.01e^{-5}$	$p = 4e^{-5}$
I/P ratio	58	0.64	(0.53 - 0.77)	$p = 2.07e^{-6}$	$p = 3.7e^{-7}$
LDH + I/P ratio	58				$p = 9.3e^{-10}$
LDH		7.80	(2.98 - 20.37)	$p = 2.8e^{-5}$ $p = 4.4e^{-6}$	
I/P ratio		0.65	(0.55 - 0.78)	$p = 4.4e^{-6}$	

^{*} Before analysis, all predictors were log-transformed.